Safety and Efficacy Study of Single-Dose Oral CEM-101 in Patients With Uncomplicated Urogenital Gonorrhea

Completed · Phase 2

Conditions studied: Uncomplicated Urogenital Gonorrhea

In brief

To determine the safety and efficacy of a single dose of solithromycin (CEM-101) for the treatment of uncomplicated urogenital gonorrhea.

Key facts

Study ID
NCT01591447
Run by
Melinta Therapeutics, Inc.
People needed
60
Starts
2012-05-01
Expected to finish
2013-06-01
Last updated by the study team
2017-03-03

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.